Clinical trial of tolerance of HPA-23 in patients with acquired immune deficiency syndrome
| Autor: | B L Moskovitz |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Adult
Antimony Male medicine.medical_specialty T-Lymphocytes medicine.medical_treatment Lymphocyte Antiviral Agents Gastroenterology Tungsten Transaminase Immune system Drug tolerance Internal medicine medicine Humans Pharmacology (medical) Aspartate Aminotransferases Adverse effect Pharmacology Acquired Immunodeficiency Syndrome Clinical Trials as Topic Chemotherapy Platelet Count business.industry Drug Tolerance Tungsten Compounds Blood Cell Count Surgery Clinical trial Infectious Diseases medicine.anatomical_structure Toxicity business Research Article |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 32:1300-1303 |
| ISSN: | 1098-6596 0066-4804 |
| DOI: | 10.1128/aac.32.9.1300 |
| Popis: | An open-label, multicenter clinical trial assessed the tolerance of HPA-23 (ammonium-21-tungsto-9-antimoniate) in patients with acquired immune deficiency syndrome. Sixty-nine patients were sequentially assigned to receive 0.25, 0.5, 1.0, or 2.0 mg of HPA-23 per kg intravenously 5 days per week for 8 weeks. HPA-23 was fairly well tolerated at doses of 1.0 mg/kg or less; nearly 60% of patients given 2.0 mg/kg discontinued treatment. Twenty-six patients discontinued treatment because of adverse events or concurrent illness. HPA-23 produced dose-related decreases in platelet count and increases in serum glutamine oxalacetic transaminase. There were no changes in immune system function, as determined by total lymphocyte count, T4-cell count, T8-cell count, and T4/T8 ratio. The effects of HPA-23 seemed to be more closely related to the total dose than to the daily dose. No improvement in the clinical status of the patients was observed during the 8 weeks of treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|